OCATA THERAPEUTICS Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OCATA THERAPEUTICS

OCAT 8.470

0.0%

Feb 11 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Savant	12/15/2010 11:40:04 AM
	of 134

(Rob)Goldman Small Cap Research Issues News Analysis Report Covering Recent Material Events at Advanced Cell Technology LOS ANGELES, CA, Dec 15, 2010 (MARKETWIRE via COMTEX) -- BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that Goldman Small Cap Research has issued a News Analysis Report which covers the recent material events at Advanced Cell Technology (ACTC). The report, which explores the strengths, weaknesses, opportunities and threats associated with an investment in Advanced Cell Technology is now available for download at BioMedReports.Com and is scheduled for full release on Wednesday afternoon by Goldman Small Cap Research. Goldman Small Cap Research was founded by Rob Goldman who has 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell-side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund. The coverage report is available now at BioMedReports.Com: biomedreports.com Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here: biomedreports.com News developments and live healthcare sector updates are available constantly via twitter at: twitter.com About BioMedReports.Com BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Media Contacts Only: Mary Davila Assistant Editor BioMedReports.Com e-mail: Email Contact Tel: +1 323 472 4480 Fax: +1 888 210 3556 SOURCE: BiomedReports

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next